New drug tested to tame autoimmune attack in Sjögren's

NCT ID NCT04572841

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study tested an experimental drug called SAR441344 to see if it could safely reduce disease activity and symptoms like fatigue in adults with primary Sjögren's syndrome. For 12 weeks, 84 participants received either the drug or a placebo (inactive substance) in a double-blind trial where neither they nor the doctors knew which they got. The main goal was to measure changes in a standard disease activity score and patient-reported symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Altoona Center For Clinical Research Site Number : 8400001

Duncansville, Pennsylvania, 16635, United States
Investigational Site Number : 0320001

San Miguel de Tucumán, Tucumán Province, T4000AXL, Argentina
Investigational Site Number : 0320002

CABA, Buenos Aires, C1111, Argentina
Investigational Site Number : 0320003

Pergamino, Buenos Aires, B2700CPM, Argentina
Investigational Site Number : 0320004

CABA, Buenos Aires, 1430, Argentina
Investigational Site Number : 0560001

Leuven, 3000, Belgium
Investigational Site Number : 0560002

Ghent, 9000, Belgium
Investigational Site Number : 1240001

Sherbrooke, Quebec, J1L 0H8, Canada
Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, 7640881, Chile
Investigational Site Number : 1520002

Osorno, Los Lagos Region, 5311092, Chile
Investigational Site Number : 1520004

Viña del Mar, Región de Valparaíso, 2520598, Chile
Investigational Site Number : 1580001

Taipei, 100, Taiwan
Investigational Site Number : 1580002

Taichung, 40447, Taiwan
Investigational Site Number : 1580003

Tainan, 704, Taiwan
Investigational Site Number : 1580005

Taoyuan, 33305, Taiwan
Investigational Site Number : 2500001

Montpellier, 34295, France
Investigational Site Number : 2500002

Strasbourg, 67098, France
Investigational Site Number : 2500003

Limoges, 87042, France
Investigational Site Number : 2500004

Paris, 75010, France
Investigational Site Number : 2500005

Marseille, 13003, France
Investigational Site Number : 2500006

Paris, 75013, France
Investigational Site Number : 2760001

Berlin, 10117, Germany
Investigational Site Number : 3480001

Debrecen, 4032, Hungary
Investigational Site Number : 3480003

Budapest, 1036, Hungary
Investigational Site Number : 3480004

Székesfehérvár, 8000, Hungary
Investigational Site Number : 4100001

Seoul, 06591, South Korea
Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, 03080, South Korea
Investigational Site Number : 4100004

Daegu, Daegu, 561-712, South Korea
Investigational Site Number : 4840001

Monterrey, Nuevo León, 64460, Mexico
Investigational Site Number : 4840002

Mexicali, Estado de Baja California, 21200, Mexico
Investigational Site Number : 4840003

Chihuahua City, 31020, Mexico
Investigational Site Number : 7240002

Málaga, 29010, Spain
Investigational Site Number : 7240003

Seville, Andalusia, 41010, Spain
Omega Research Consultants Debary Site Number : 8400005

DeBary, Florida, 32713, United States
Prolato Clinical Research Center Site Number : 8400009

Houston, Texas, 77054, United States
Ramesh C. Gupta, M.D. Site Number : 8400007

Memphis, Tennessee, 38119, United States

Conditions

Explore the condition pages connected to this study.

SJOGREN'S SYNDROME SJÖGREN´S SYNDROME